BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.42
+0.12 (1.64%)
Nov 21, 2024, 1:44 PM EST - Market open
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for BCRX stock have an average target of 15.6, with a low estimate of 8.00 and a high estimate of 30. The average target predicts an increase of 110.24% from the current stock price of 7.42.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BCRX stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 2 | 2 | 2 | 2 |
Buy | 3 | 3 | 3 | 3 | 3 | 2 |
Hold | 0 | 0 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 7 | 6 | 6 | 6 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
RBC Capital | RBC Capital | Buy Reiterates $10 | Buy | Reiterates | $10 | +34.77% | Nov 5, 2024 |
Needham | Needham | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +88.68% | Nov 5, 2024 |
Barclays | Barclays | Hold Maintains $7 → $8 | Hold | Maintains | $7 → $8 | +7.82% | Nov 5, 2024 |
JMP Securities | JMP Securities | Buy Maintains $15 → $16 | Buy | Maintains | $15 → $16 | +115.63% | Aug 6, 2024 |
Barclays | Barclays | Hold Maintains $6 → $7 | Hold | Maintains | $6 → $7 | -5.66% | Aug 6, 2024 |
Financial Forecast
Revenue This Year
454.83M
from 331.41M
Increased by 37.24%
Revenue Next Year
542.60M
from 454.83M
Increased by 19.30%
EPS This Year
-0.38
from -1.18
EPS Next Year
-0.06
from -0.38
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 476.7M | 577.5M | 697.7M | ||
Avg | 454.8M | 542.6M | 626.3M | ||
Low | 421.8M | 496.2M | 553.7M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 43.8% | 27.0% | 28.6% | ||
Avg | 37.2% | 19.3% | 15.4% | ||
Low | 27.3% | 9.1% | 2.0% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.32 | 0.12 | 0.57 | ||
Avg | -0.38 | -0.06 | 0.28 | ||
Low | -0.45 | -0.23 | -0.07 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.